- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 33 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.6: 11 residues within 4Å:- Chain A: V.259, L.266, N.267, R.309, N.380, G.382, R.443, C.444, V.445, S.446
- Ligands: NAG-NAG.9
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:V.445
- Hydrogen bonds: A:G.382, A:V.445
NAG-NAG-BMA-MAN-MAN-MAN.20: 11 residues within 4Å:- Chain D: E.216, V.259, L.266, N.267, R.309, N.380, G.382, C.444, V.445, S.446
- Ligands: NAG-NAG.23
3 PLIP interactions:3 interactions with chain D- Hydrophobic interactions: D:V.445
- Hydrogen bonds: D:G.382, D:V.445
NAG-NAG-BMA-MAN-MAN-MAN.34: 10 residues within 4Å:- Chain G: E.216, V.259, L.266, N.267, R.309, G.382, C.444, V.445, S.446
- Ligands: NAG-NAG.37
3 PLIP interactions:3 interactions with chain G- Hydrophobic interactions: G:V.445
- Hydrogen bonds: G:G.382, G:V.445
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.11: 17 residues within 4Å:- Chain A: N.300, T.302, R.331, H.334, N.336
- Chain B: S.24, N.44, N.45, P.60, G.61, S.62
- Chain C: R.102, R.103, I.104, G.106, V.107, V.108
3 PLIP interactions:1 interactions with chain C, 2 interactions with chain A- Hydrophobic interactions: C:V.108
- Hydrogen bonds: C:V.108, A:R.331, A:R.331, C:R.102
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.25: 17 residues within 4Å:- Chain D: N.300, T.302, R.331, H.334, N.336
- Chain E: S.24, N.44, N.45, P.60, G.61, S.62
- Chain F: R.102, R.103, I.104, G.106, V.107, V.108
3 PLIP interactions:2 interactions with chain D, 1 interactions with chain F- Hydrogen bonds: D:R.331, D:R.331, F:V.108, F:R.102
- Hydrophobic interactions: F:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN.39: 17 residues within 4Å:- Chain G: N.300, T.302, R.331, H.334, N.336
- Chain H: S.24, N.44, N.45, P.60, G.61, S.62
- Chain I: R.102, R.103, I.104, G.106, V.107, V.108
3 PLIP interactions:2 interactions with chain G, 1 interactions with chain I- Hydrogen bonds: G:R.331, G:R.331, I:V.108, I:R.102
- Hydrophobic interactions: I:V.108
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.14: 16 residues within 4Å:- Chain A: N.145
- Chain B: W.88, D.89, R.92, T.94
- Chain C: Y.33, H.52, S.54, G.55, D.56, T.57, N.58, H.100, R.102, F.114, T.115
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:N.58, C:T.57
NAG-NAG-BMA-MAN-MAN-MAN.28: 16 residues within 4Å:- Chain D: N.145
- Chain E: W.88, D.89, R.92, T.94
- Chain F: Y.33, H.52, S.54, G.55, D.56, T.57, N.58, H.100, R.102, F.114, T.115
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:N.58, F:T.57
NAG-NAG-BMA-MAN-MAN-MAN.42: 16 residues within 4Å:- Chain G: N.145
- Chain H: W.88, D.89, R.92, T.94
- Chain I: Y.33, H.52, S.54, G.55, D.56, T.57, N.58, H.100, W.113, F.114, T.115
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:N.58, I:T.57
- 15 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.43: 5 residues within 4Å:- Chain A: N.137, S.160, F.161, N.162
- Ligands: NAG-NAG.2
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain A: P.185, N.195, Y.196
Ligand excluded by PLIPNAG.45: 5 residues within 4Å:- Chain A: E.273, E.274, N.294, E.295, Q.348
Ligand excluded by PLIPNAG.46: 2 residues within 4Å:- Chain A: G.339, N.343
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain A: P.603, W.604, N.605
Ligand excluded by PLIPNAG.48: 5 residues within 4Å:- Chain D: N.137, S.160, F.161, N.162
- Ligands: NAG-NAG.16
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain D: P.185, N.195, Y.196
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain D: E.273, E.274, N.294, E.295, Q.348
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain D: G.339, N.343, D.411
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain D: P.603, W.604, N.605
Ligand excluded by PLIPNAG.53: 5 residues within 4Å:- Chain G: N.137, S.160, F.161, N.162
- Ligands: NAG-NAG.30
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain G: P.185, N.195, Y.196
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain G: E.273, E.274, N.294, E.295, Q.348
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain G: G.339, N.343, D.411
Ligand excluded by PLIPNAG.57: 3 residues within 4Å:- Chain G: P.603, W.604, N.605
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, G.M. et al., Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens. Npj Vaccines (2023)
- Release Date
- 2022-03-09
- Peptides
- Env glycoprotein gp160: ADG
PGT122 Fab light chain: BEH
PGT122 Fab heavy chain: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
LE
MH
OC
HF
NI
P
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 33 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 15 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, G.M. et al., Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens. Npj Vaccines (2023)
- Release Date
- 2022-03-09
- Peptides
- Env glycoprotein gp160: ADG
PGT122 Fab light chain: BEH
PGT122 Fab heavy chain: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
LE
MH
OC
HF
NI
P